Please join us for a workshop on developing SBIR grants.

Thursday, January 24th, 2019 from 11 am - 1 pm
Lory Student Center
Longs Peak Room (#302)

Lunch Provided, Registration REQUIRED

Register Now!

You MUST register to receive the complimentary lunch.  Registration closes at 50 participants. 

Agenda

11:00 am -11:30 am:  Crash Course on Federal SBIR/STTR programs 
11:30 am -12:15 pm:  SBIR Awardees Panel
12:15 pm - 1:00 pm:    Group Breakouts*

*Group Breakouts provide the opportunity to sit with individual panel members to discuss strategies, common pitfalls, other SBIR specifics.

Guest Panel

  Scott Fullbright, PhD
  CEO and Co-Founder, Living Ink Technologies
  NSF SBIR

 Scott is the CEO and co-founder of Living Ink, a Colorado-based company developing eco-friendly
 pigments for a variety of markets including ink, cosmetics, and plastics.  Living Ink has raised a
 combined $1.5M in federal and state grant programs.  Prior to Living Ink, Scott spent the last 12
 years in the algae bioproducts industry, where he led R&D projects in both industry and academia. 
 He received his PhD from Colorado State University in Cell and Molecular Biologies.

 Tom Reilly, PhD
 CSO and Co-Founder, Access Sensor Technologies
 NSF, NIH, USDA, NOAA SBIR

 Tom is a Ph.D. chemist with much of his research background involving functional materials,   instrumentation and sensor development. He was the first hire at Access Sensor Technologies, a CSU spin-
 out company formed in 2013. The company has been fortunate to receive funding for environmental
 diagnostic concepts from the NSF, NIH-NIEHS, CDC-NIOSH, USDA and NOAA SBIR programs. Using SBIR
 funds the company has advanced several early-stage concepts. To date, two product lines have been
 brought to market that were funded in part through SBIR grants.

Brian Heinze, PhD
 R&D Director, Optienz Sensors
NSF SBIR

Brian is R&D Director at OptiEnz Sensors where he leads technical development and grant based
fundraising activities. He earned a B.S. degree in biology and a Ph.D. in biosystems engineering, both
with honors from the University of Arizona. His dissertation, entitled “Optical Immunosensors for Pathogen
Detection,” was focused on designing portable optical antibody-based biosensors. Brian has been actively
involved in researching and developing optical biosensors for more than ten years. Previously, he worked
as a post-doctoral researcher at OptiEnz Sensors and a research scientist at Colorado State University.
He also operated a research consulting company that developed chemical sensors for defense-related
projects. 

 Rodman Tompkins
 Director of Licencing and Business Development, CSU Ventures
 Executive Vice President - Technology Strategy, Mantel Technologies
 DoD SBIR

 Rod joined CSUV in 2008 and is a Director of Licensing and Business Development for the
 Infectious Disease portfolio, and an eclectic mix of other technologies ranging from neuroscience
 and reproductive biology to atmospheric sciences.  Rod co-founded and helps manage Mantel
 Technologies, a government contracting start-up formed by CSU Ventures to actively transition
 technologies that can be matched to specific government needs. Rod earned MS degrees in
 neuroscience and infectious disease from CSU.

 Richard Duke
 CSO and Founder; Colorado Institute for Drug, Device and Diagnostic Development (CID4)
 NIH SBIR

 Dr. Duke is a biotechnology executive, inventor, biomedical researcher and serial entrepreneur with 15
 years of experience in building, financing, and managing start-up biotechnology companies based on
 inventions made in Colorado’s non-profit research institutions. He is currently Co-scientific Founder,
 President and CEO of ApopLogic Pharmaceuticals. Dr. Duke is a Co-scientific Founder and former CEO,
 President and Director of GlobeImmune, Inc. and was involved in the formation of Sierra Neuropharmaceuticals where he was an initial Director. These Colorado-based companies have raised more than $150 million in financing and have  multiple products in phase 1 and 2 human clinical trials. In addition to his entrepreneurial activities, Dr. Duke has over twenty-five years of experience in cutting-edge biomedical research and is a tenured faculty member in the Departments of Medicine (Medical Oncology) and Immunology at the University of Colorado Denver. Dr. Duke has provided independent 3rd-party research analysis in the life sciences sector to Janus Capital and to venture capital firms.

  Event sponsored by: